Navigation Links
Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
Date:11/19/2010

SAN DIEGO, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that it was notified on November 16, 2010 by the Listing Qualifications Staff of The NASDAQ Stock Market that, due to the Company's non-compliance with the minimum $10 million stockholders' equity requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(b)(1), the Company's common stock is subject to delisting unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel. The Company intends to timely request a hearing before the Panel, which request will stay any further action by NASDAQ until the Panel issues its decision following the hearing. In connection with the hearing, the Panel may grant the Company an additional compliance period of up to 180 calendar days from the date of the NASDAQ staff's determination, or May 16, 2011, to evidence compliance with the minimum stockholders' equity requirement for continued listing on The NASDAQ Global Market. While the Company is working diligently to remedy the listing deficiency, there can be no assurance that the Panel will grant the Company's request for continued listing on The NASDAQ Global Market and, if the Panel does not, the Company's common stock may be transferred to The NASDAQ Capital Market or delisted from NASDAQ.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's pipeline is derived from an investigational isoflavone technology platform that has generated a number of compounds with anti-proliferative activity in human cancer cell lines. These small molecules have been shown to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. The Company's lead programs focus on two families of compounds with related but distinct mechanisms of action. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
2. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
3. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. CryoCor Receives FDA Approval for Right Atrial Flutter
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
(Date:12/2/2016)... Dec. 2, 2016 CVS Health Corporation (NYSE: ... Day in New York City on Thursday, December 15, 2016, beginning at 8:00 ... team will provide an in-depth review of the company,s ... The company will also discuss 2017 earnings guidance during ... of the event will be broadcast simultaneously on the ...
(Date:12/2/2016)... 2016 Lianluo Smart Limited (Nasdaq: ... which develops, markets and sells medical devices and ... and international markets, recently attended the ... New Progress Forum, co-hosted by the Institute of ... , Guangdong Provincial People,s Hospital and Cardiology Department ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released study ... the reproducibility and accuracy of placing precordial electrodes with little cognitive effort and ... last 60 years, studies have shown that single electrode misplacement is one of ...
(Date:12/4/2016)... , ... December 03, 2016 , ... ... 4 transitions and many more tools allowing FCPX editors to create professional looking ... Film Studios. , Perfect Harmony contains a beautifully designed 3D environment for ...
(Date:12/4/2016)... ... 03, 2016 , ... Penrose Senior Care Auditors® was announced ... evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and Banquet ... for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, commitment ...
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold In Your ... experienced Indoor Air Quality Companies in VA, MD and DC, recently completed its application ... The new mold law in the district of Columbia is a good thing stated ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
Breaking Medicine News(10 mins):